Mast Cell Activation Syndrome (MCAS)
Over the years, as I treated patients with Lyme disease and other vector-borne infections, as well as mold toxicity, I began to notice a pattern. While many people improved as expected, a subset of patients either did not fully recover or presented with a different constellation of symptoms — reactions that seemed out of proportion, unpredictable, or difficult to explain through infection or environmental exposure alone.
I’ve come to view the health care journey as one of identifying and addressing pieces to a puzzle. For some individuals, Lyme disease may be the primary driver of symptoms (or puzzle piece). For others, multiple contributors overlap, each influencing the overall picture. Recognizing which pieces matter most — and when — is often key to meaningful progress.
A turning point for me came during an International Lyme and Associated Diseases Society conference in the mid-2010's, when Lawrence Afrin, MD presented on Mast Cell Activation Syndrome. As he described symptom patterns and clinical presentations, I vividly recall thinking of multiple patients I had already seen — individuals whose experiences suddenly made sense in a new way.
When I returned to the clinic the following week, I began incorporating mast cell evaluation into my differential diagnosis and, when appropriate, carefully trialing mast cell–directed treatment. The results were striking. Many patients experienced significant improvement, and in some cases, symptoms resolved entirely. Just as importantly, for individuals with underlying Lyme disease or other chronic conditions, addressing mast cell activation often made it easier for the body respond to treatment and recover.
Since then, Mast Cell Activation Syndrome has become an essential consideration in my work with complex, multisystem illness. Understanding MCAS has added another critical layer to patient care — one that has helped many people move forward after feeling stuck for far too long.
I’ve come to view the health care journey as one of identifying and addressing pieces to a puzzle. For some individuals, Lyme disease may be the primary driver of symptoms (or puzzle piece). For others, multiple contributors overlap, each influencing the overall picture. Recognizing which pieces matter most — and when — is often key to meaningful progress.
A turning point for me came during an International Lyme and Associated Diseases Society conference in the mid-2010's, when Lawrence Afrin, MD presented on Mast Cell Activation Syndrome. As he described symptom patterns and clinical presentations, I vividly recall thinking of multiple patients I had already seen — individuals whose experiences suddenly made sense in a new way.
When I returned to the clinic the following week, I began incorporating mast cell evaluation into my differential diagnosis and, when appropriate, carefully trialing mast cell–directed treatment. The results were striking. Many patients experienced significant improvement, and in some cases, symptoms resolved entirely. Just as importantly, for individuals with underlying Lyme disease or other chronic conditions, addressing mast cell activation often made it easier for the body respond to treatment and recover.
Since then, Mast Cell Activation Syndrome has become an essential consideration in my work with complex, multisystem illness. Understanding MCAS has added another critical layer to patient care — one that has helped many people move forward after feeling stuck for far too long.
What Is Mast Cell Activation Syndrome (MCAS)?
Mast Cell Activation Syndrome (MCAS) is a multisystem condition in which mast cells—immune cells that play a role in inflammation, defense, and tissue repair—become overly reactive or release their chemical mediators inappropriately. Rather than responding only to true threats, mast cells in MCAS may activate too easily, too often, and sometimes without a clear trigger.
Mast cells are found throughout the body, including the skin, gastrointestinal tract, lungs, blood vessels, and nervous system. When activated, they release substances such as histamine, prostaglandins, leukotrienes, cytokines, and other mediators. In MCAS, the release of histamine and other mediators can affect multiple organ systems, leading to a wide range of symptoms that may fluctuate over time.
MCAS is different from a classic allergy. Unlike IgE-mediated allergic reactions, MCAS does not always involve a specific allergen, positive allergy testing, or predictable reactions. Symptoms may be episodic, variable, and triggered by factors such as foods, medications, temperature changes, stress, infections, or environmental exposures, including mold.
Mast Cell Activation Syndrome is also distinct from mastocytosis, a rare condition characterized by an increased number of mast cells. In mastocytosis, a blood test called serum tryptase is typically elevated, reflecting increased mast cell burden. In MCAS, tryptase levels are usually normal, as the condition involves inappropriate mast cell activation (release of mediators like histamine) rather than excess mast cells.
Understanding how mast cell activation contributes to symptoms is an important step toward identifying patterns, reducing triggers, and supporting stabilization over time.
Mast cells are found throughout the body, including the skin, gastrointestinal tract, lungs, blood vessels, and nervous system. When activated, they release substances such as histamine, prostaglandins, leukotrienes, cytokines, and other mediators. In MCAS, the release of histamine and other mediators can affect multiple organ systems, leading to a wide range of symptoms that may fluctuate over time.
MCAS is different from a classic allergy. Unlike IgE-mediated allergic reactions, MCAS does not always involve a specific allergen, positive allergy testing, or predictable reactions. Symptoms may be episodic, variable, and triggered by factors such as foods, medications, temperature changes, stress, infections, or environmental exposures, including mold.
Mast Cell Activation Syndrome is also distinct from mastocytosis, a rare condition characterized by an increased number of mast cells. In mastocytosis, a blood test called serum tryptase is typically elevated, reflecting increased mast cell burden. In MCAS, tryptase levels are usually normal, as the condition involves inappropriate mast cell activation (release of mediators like histamine) rather than excess mast cells.
Understanding how mast cell activation contributes to symptoms is an important step toward identifying patterns, reducing triggers, and supporting stabilization over time.
Common Symptoms of MCAS
Symptoms of Mast Cell Activation Syndrome and histamine-related disorders can vary widely and may involve multiple organ systems. Reactions can sometimes be correlated with specific triggers but are often episodic and may fluctuate over time, making patterns difficult to recognize.
Common symptoms may include:
Skin
Gastrointestinal
Cardiovascular
Neurologic
Respiratory
Oral and Facial
Pelvic and Genitourinary
Other
Not everyone experiences all of these symptoms, and severity can range from mild to debilitating. Recognizing symptom patterns across systems can be an important step toward identifying mast cell involvement.
Common symptoms may include:
Skin
- Flushing or redness
- Itching or hives
- Rashes
- Heat sensitivity
Gastrointestinal
- Abdominal pain or cramping
- Bloating
- Nausea
- Diarrhea or loose stools
- Acid reflux
Cardiovascular
- Heart palpitations
- Lightheadedness or dizziness
- Blood pressure fluctuations
- Feeling faint
Neurologic
- Brain fog or difficulty concentrating
- Headaches or migraines
- Anxiety
- Depression
- Mood swings
- Seizures
- Sleep disturbance
Respiratory
- Shortness of breath or air hunger
- Chest tightness
- Wheezing
- Nasal congestion
- Runny nose
- Sinusitis
- Sore throat
- Throat tightness
Oral and Facial
- Tongue swelling
- Lip swelling
- Mouth or facial swelling
- Choking
Pelvic and Genitourinary
- Bladder pain
- Interstitial cystitis–like symptoms
- Vaginitis
- Prostatitis
Other
- Food, medication or supplement sensitivities
- Temperature intolerance
- Fatigue
- Worsening of symptoms during stress, illness, or hormonal changes
Not everyone experiences all of these symptoms, and severity can range from mild to debilitating. Recognizing symptom patterns across systems can be an important step toward identifying mast cell involvement.
Why MCAS Is Often Missed or Misdiagnosed
Mast Cell Activation Syndrome is frequently overlooked because its symptoms are variable, multisystem, and often episodic. Individuals may experience symptoms that come and go, change over time, or affect different body systems without an obvious unifying explanation.
Routine laboratory testing and imaging are often normal or only mildly abnormal in people with MCAS. When symptoms resemble conditions such as panic disorders, irritable bowel syndrome, migraines, allergies, or autonomic dysfunction, the broader clinical picture may be missed, limiting recognition and treatment of mast cell involvement.
Another challenge is that mast cell mediators are released intermittently. Many laboratory markers, such as histamine, may only be elevated during or shortly after a flare, making timing critical and false-negative results common.
Another challenge is that laboratory testing for mast cell mediators is prone to false-negative results for both logistical and technical reasons. First, mast cell mediators are released intermittently from the mast cell. Once a sample is taken, mast cell mediators degrade quickly, and sample handling is critical. Factors such as timing of collection, temperature control, transport delays, and laboratory familiarity with proper processing can significantly affect results. In addition, recent use of certain foods, medications, or supplements may further reduce test sensitivity.
As a result, normal laboratory results do not exclude mast cell activation. While formal diagnostic criteria include laboratory support, clinical judgment remains essential. In practice, a consistent symptom pattern and a meaningful response to treatment may be sufficient to support a suspected diagnosis and guide ongoing care focused on symptom relief and stabilization.
MCAS is often identified only after other explanations have been exhausted. A careful clinical history, attention to symptom patterns and triggers, and an integrative perspective are essential in recognizing mast cell activation as a contributing factor to health problems.
Routine laboratory testing and imaging are often normal or only mildly abnormal in people with MCAS. When symptoms resemble conditions such as panic disorders, irritable bowel syndrome, migraines, allergies, or autonomic dysfunction, the broader clinical picture may be missed, limiting recognition and treatment of mast cell involvement.
Another challenge is that mast cell mediators are released intermittently. Many laboratory markers, such as histamine, may only be elevated during or shortly after a flare, making timing critical and false-negative results common.
Another challenge is that laboratory testing for mast cell mediators is prone to false-negative results for both logistical and technical reasons. First, mast cell mediators are released intermittently from the mast cell. Once a sample is taken, mast cell mediators degrade quickly, and sample handling is critical. Factors such as timing of collection, temperature control, transport delays, and laboratory familiarity with proper processing can significantly affect results. In addition, recent use of certain foods, medications, or supplements may further reduce test sensitivity.
As a result, normal laboratory results do not exclude mast cell activation. While formal diagnostic criteria include laboratory support, clinical judgment remains essential. In practice, a consistent symptom pattern and a meaningful response to treatment may be sufficient to support a suspected diagnosis and guide ongoing care focused on symptom relief and stabilization.
MCAS is often identified only after other explanations have been exhausted. A careful clinical history, attention to symptom patterns and triggers, and an integrative perspective are essential in recognizing mast cell activation as a contributing factor to health problems.
Triggers and Contributing Factors
Mast cell activation can be influenced by a wide range of internal and external factors. In many individuals, symptoms do not arise from a single trigger but rather from a cumulative burden that lowers the threshold for mast cell activation over time.
Common triggers and contributing factors may include infections such as Lyme disease and other tick-borne illnesses, viral infections, and chronic inflammatory conditions. Environmental exposures, including mold and mycotoxins, are also recognized mast cell triggers and may worsen symptom severity or persistence.
Physiologic stressors can further influence mast cell activity. Hormonal fluctuations, physical stress, emotional stress, sleep disruption, and temperature changes are commonly reported contributors. Certain foods, medications, supplements, fragrances, and chemical exposures may also provoke symptoms, even if previously tolerated.
In some individuals, mast cell activation appears to develop or worsen following a significant illness, environmental exposure, or period of sustained stress. Over time, this can lead to increasing reactivity and a narrowing window of tolerance.
Identifying personal triggers and contributing factors is an important part of care. Reducing exposures where possible and addressing upstream drivers can help support stabilization and symptom improvement.
Common triggers and contributing factors may include infections such as Lyme disease and other tick-borne illnesses, viral infections, and chronic inflammatory conditions. Environmental exposures, including mold and mycotoxins, are also recognized mast cell triggers and may worsen symptom severity or persistence.
Physiologic stressors can further influence mast cell activity. Hormonal fluctuations, physical stress, emotional stress, sleep disruption, and temperature changes are commonly reported contributors. Certain foods, medications, supplements, fragrances, and chemical exposures may also provoke symptoms, even if previously tolerated.
In some individuals, mast cell activation appears to develop or worsen following a significant illness, environmental exposure, or period of sustained stress. Over time, this can lead to increasing reactivity and a narrowing window of tolerance.
Identifying personal triggers and contributing factors is an important part of care. Reducing exposures where possible and addressing upstream drivers can help support stabilization and symptom improvement.
Evaluation and Testing for MCAS
Evaluation for Mast Cell Activation Syndrome requires a thoughtful, clinically guided approach. At this time, the medical diagnosis of MCAS is defined by the fulfillment of three consensus criteria: characteristic clinical features consistent with mast cell mediator release, objective laboratory evidence of mast cell activation, and a response to appropriate mast cell–directed therapy.
When elevated, laboratory testing can provide important objective support for the diagnosis. However, mast cell mediators are released intermittently and degrade rapidly. The accuracy of testing is highly dependent on timing, temperature control, transport conditions, and proper laboratory handling. Recent use of certain foods, medications, or supplements may also suppress mediator release and contribute to false-negative results. As a result, normal laboratory findings do not exclude mast cell activation.
In practice, when objective testing is limited or inconclusive, a consistent symptom pattern combined with a meaningful response to mast cell–directed treatment may be sufficient to support a suspected diagnosis and guide ongoing care focused on symptom relief and stabilization, while continuing to reassess as clinically appropriate.
When elevated, laboratory testing can provide important objective support for the diagnosis. However, mast cell mediators are released intermittently and degrade rapidly. The accuracy of testing is highly dependent on timing, temperature control, transport conditions, and proper laboratory handling. Recent use of certain foods, medications, or supplements may also suppress mediator release and contribute to false-negative results. As a result, normal laboratory findings do not exclude mast cell activation.
In practice, when objective testing is limited or inconclusive, a consistent symptom pattern combined with a meaningful response to mast cell–directed treatment may be sufficient to support a suspected diagnosis and guide ongoing care focused on symptom relief and stabilization, while continuing to reassess as clinically appropriate.
Treatment Considerations for MCAS
Treatment of Mast Cell Activation Syndrome focuses on stabilizing mast cells, reducing mediator release, and minimizing triggers, while addressing underlying contributors when possible. Management is highly individualized and often requires a stepwise, paced approach.
An important early goal is identifying and reducing triggers that provoke mast cell activation. This may include dietary modifications (low histamine diet), adjustments to medications or supplements, and minimizing exposure to environmental factors such as mold, chemicals, fragrances, or temperature changes. Stress management and nervous system support are also important, as physiologic and emotional stress can amplify mast cell reactivity.
Pharmaceutical and natural therapies are commonly used to block mast cell mediators or stabilize mast cells. These may include antihistamines targeting different histamine receptors and mast cell stabilizers, selected based on symptom patterns and tolerance. Treatment is often introduced gradually to reduce the risk of symptom flares.
For many individuals, addressing upstream drivers—such as chronic infections (like Lyme disease), environmental exposures (such as mold), or hormonal imbalances—is essential for sustained improvement. Care is typically layered over time, rather than implemented all at once, with close monitoring and adjustment based on response.
Progress with MCAS is often nonlinear. Stabilization and symptom relief may occur gradually, and treatment plans evolve as tolerance improves. A flexible, patient-centered approach helps support steady improvement while minimizing setbacks.
An important early goal is identifying and reducing triggers that provoke mast cell activation. This may include dietary modifications (low histamine diet), adjustments to medications or supplements, and minimizing exposure to environmental factors such as mold, chemicals, fragrances, or temperature changes. Stress management and nervous system support are also important, as physiologic and emotional stress can amplify mast cell reactivity.
Pharmaceutical and natural therapies are commonly used to block mast cell mediators or stabilize mast cells. These may include antihistamines targeting different histamine receptors and mast cell stabilizers, selected based on symptom patterns and tolerance. Treatment is often introduced gradually to reduce the risk of symptom flares.
For many individuals, addressing upstream drivers—such as chronic infections (like Lyme disease), environmental exposures (such as mold), or hormonal imbalances—is essential for sustained improvement. Care is typically layered over time, rather than implemented all at once, with close monitoring and adjustment based on response.
Progress with MCAS is often nonlinear. Stabilization and symptom relief may occur gradually, and treatment plans evolve as tolerance improves. A flexible, patient-centered approach helps support steady improvement while minimizing setbacks.
MCAS and Chronic Illness
Mast Cell Activation Syndrome frequently overlaps with chronic illness and may contribute to persistent, multisystem symptoms when recovery has stalled. Ongoing mast cell activation can amplify inflammation, disrupt nervous system balance, and increase sensitivity across multiple body systems.
In clinical practice, MCAS is often seen alongside conditions such as chronic infections (including Lyme disease and other tick-borne illnesses), mycotoxicity, autonomic dysfunction, mast cell–mediated gastrointestinal disorders, and hormonal imbalances. When these conditions coexist, symptoms may become more complex, variable, and difficult to attribute to a single cause.
Chronic immune activation and environmental stressors can lower the threshold for mast cell reactivity over time. As a result, individuals may notice increasing sensitivity to foods, medications, supplements, temperature changes, or stressors that were previously well tolerated. This pattern can help explain why symptoms may evolve or intensify rather than resolve.
Recognizing mast cell activation within the broader context of chronic illness allows for a more comprehensive and integrated approach to care. Addressing MCAS alongside contributing factors can be an important step toward improved stability and symptom relief, particularly for individuals who have not experienced full improvement with other treatments.
In clinical practice, MCAS is often seen alongside conditions such as chronic infections (including Lyme disease and other tick-borne illnesses), mycotoxicity, autonomic dysfunction, mast cell–mediated gastrointestinal disorders, and hormonal imbalances. When these conditions coexist, symptoms may become more complex, variable, and difficult to attribute to a single cause.
Chronic immune activation and environmental stressors can lower the threshold for mast cell reactivity over time. As a result, individuals may notice increasing sensitivity to foods, medications, supplements, temperature changes, or stressors that were previously well tolerated. This pattern can help explain why symptoms may evolve or intensify rather than resolve.
Recognizing mast cell activation within the broader context of chronic illness allows for a more comprehensive and integrated approach to care. Addressing MCAS alongside contributing factors can be an important step toward improved stability and symptom relief, particularly for individuals who have not experienced full improvement with other treatments.
Who Is at Higher Risk?
Not everyone exposed to potential mast cell triggers develops Mast Cell Activation Syndrome. Individual susceptibility varies, and certain factors appear to increase the likelihood of developing persistent or more severe symptoms.
MCAS is reported more frequently in females, suggesting a possible role for hormonal influences. Genetic predispositions also contribute to risk. Individuals with hypermobility spectrum disorders or Ehlers–Danlos syndrome (EDS) appear to be at higher risk, as do those with underlying immune deficiencies.
Additional contributors may include a history of chronic infections, environmental exposures such as mold, autonomic dysfunction, and cumulative physiologic stress. Recognizing risk factors can help guide evaluation, inform pacing of treatment, and support individualized care planning.
MCAS is reported more frequently in females, suggesting a possible role for hormonal influences. Genetic predispositions also contribute to risk. Individuals with hypermobility spectrum disorders or Ehlers–Danlos syndrome (EDS) appear to be at higher risk, as do those with underlying immune deficiencies.
Additional contributors may include a history of chronic infections, environmental exposures such as mold, autonomic dysfunction, and cumulative physiologic stress. Recognizing risk factors can help guide evaluation, inform pacing of treatment, and support individualized care planning.
Living With MCAS
Living with Mast Cell Activation Syndrome can feel unpredictable, particularly when symptoms fluctuate or reactions seem disproportionate to triggers. Over time, many individuals learn that stability comes from understanding personal patterns, reducing exposure to known triggers, and pacing care thoughtfully.
Progress with MCAS often involves shifting from reacting to symptoms toward creating predictability where possible. This may include consistent medication or supplement routines, careful introduction of new foods or therapies, and attention to sleep, stress regulation, and nervous system support. Small, steady adjustments can make a meaningful difference.
Importantly, improvement does not require perfection. Setbacks can occur, particularly during illness, stress, or environmental changes. These fluctuations do not negate progress and are often part of the stabilization process.
With appropriate support and an individualized approach, many people find that symptoms become more manageable over time, allowing for improved function, confidence, and quality of life.
Progress with MCAS often involves shifting from reacting to symptoms toward creating predictability where possible. This may include consistent medication or supplement routines, careful introduction of new foods or therapies, and attention to sleep, stress regulation, and nervous system support. Small, steady adjustments can make a meaningful difference.
Importantly, improvement does not require perfection. Setbacks can occur, particularly during illness, stress, or environmental changes. These fluctuations do not negate progress and are often part of the stabilization process.
With appropriate support and an individualized approach, many people find that symptoms become more manageable over time, allowing for improved function, confidence, and quality of life.
Working Together
Navigating Mast Cell Activation Syndrome can be challenging, particularly when symptoms have been persistent, variable, or difficult to explain. A thoughtful, individualized approach can help bring clarity, stability, and direction over time.
My work focuses on helping individuals understand how mast cell activation may be contributing to their symptoms and on developing a step-by-step care plan that prioritizes safety, pacing, and whole-person support. Evaluation and recommendations are tailored to each individual’s history, triggers, symptom patterns, and goals.
Care is provided via telehealth, with services adapted based on location and licensure. Specific details are reviewed during the intake and consent process to ensure clarity and transparency.
If you are seeking guidance related to MCAS, histamine-related symptoms, or complex multisystem illness, working together may help identify next steps and support progress toward improved stability and quality of life.
To learn more about scheduling options or to schedule an appointment, please visit:
👉 Schedule an Appointment
My work focuses on helping individuals understand how mast cell activation may be contributing to their symptoms and on developing a step-by-step care plan that prioritizes safety, pacing, and whole-person support. Evaluation and recommendations are tailored to each individual’s history, triggers, symptom patterns, and goals.
Care is provided via telehealth, with services adapted based on location and licensure. Specific details are reviewed during the intake and consent process to ensure clarity and transparency.
If you are seeking guidance related to MCAS, histamine-related symptoms, or complex multisystem illness, working together may help identify next steps and support progress toward improved stability and quality of life.
To learn more about scheduling options or to schedule an appointment, please visit:
👉 Schedule an Appointment
All material provided on this website is provided for informational or educational purposes only,
and is not intended as a substitute for the advice provided by your physician or healthcare professional.